This new line of pharmaceuticals maximizes the beneficial effects on energy and glucose metabolism while minimizing unwanted side-effects (Tschop and DiMarchi, Glucagon (Gcg) has many beneficial effects on energy homeostasis including the inhibition of food intake, as well as the ability to increase energy expenditure and activate BAT which all lead to a reduction in body weight (reviewed in Habegger et al., Glp1r/ mice treated with the GLP-1/Gcg coagonist experienced a reduction in body weight and fat mass but did not have improvements in glucose tolerance indicating that GLP-1R agonism is required to counteract the hyperglycemic effects of GcgR agonism (Day et al., Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone released from the K-cells of the small intestines and acts on the pancreas to potentiate GSIS (Miyawaki et al., An alternative approach aiming to maximize the efficacy of GLP-1 involves the delivery of nuclear receptor agonists to specific tissues characterized by the expression of GLP-1R
For patients with BMIs that started above 35, significant metabolic syndrome, or a history of yo-yo dieting, maintenance dosing often produces the best long-term outcomes
What will the next 10-20 years look like if you dont address your weight
You can u003ca href=u0022#can-i-use-my-hsa-for-semaglutide-or-tirzepatideu0022u003euse your HSAu003c/au003e to pay for GLP-1 medication as long as it is prescribed for a legitimate medical condition such as obesity, insulin resistance, type 2 diabetes, or metabolic dysfunction
